Patients simply wear the ring on a finger, allowing blood pressure measurements to be automatically recorded
A small ring worn on the finger has quietly reshaped how one of the world's most medically advanced nations monitors the silent pressure building inside its citizens' arteries. Sky Labs' CART BP pro, adopted by 81 percent of Korea's tertiary hospitals within 18 months of launch, represents something rarer than a successful product: a solution that dissolves the friction between what medicine knows is best and what patients are willing to endure. In removing the cuff, the company may have removed the last excuse for incomplete cardiovascular data — and in doing so, opened a new chapter in how hypertension is understood and treated.
- For decades, the most clinically valuable blood pressure test — continuous 24-hour monitoring — has been quietly abandoned by physicians who knew patients would resist the discomfort of a repeatedly inflating arm cuff through the night.
- A finger ring that records blood pressure without compression or interruption has broken that impasse, spreading to 38 of Korea's 47 top-tier hospitals and nearly 2,000 smaller clinics in just a year and a half.
- Korea's Society of Hypertension formalized the shift in 2026, updating clinical guidelines to explicitly permit validated cuffless monitors — giving hospitals and doctors institutional cover to fully embrace the technology.
- With all five of Korea's largest hospital networks now using the device, Sky Labs is positioning its domestic dominance as proof of concept for expansion into global markets where the same patient-compliance problem persists.
- The deeper consequence is clinical: doctors can now see morning blood pressure surges, overnight patterns, and day-long variability that were previously invisible — enabling diagnoses and treatments that were simply out of reach before.
A South Korean medical device company has achieved a remarkable milestone: its finger-worn blood pressure monitor is now standard equipment in 81 percent of Korea's tertiary hospitals, including all five of the nation's largest hospital networks, just 18 months after launch.
The device, Sky Labs' CART BP pro, addresses a problem that has quietly undermined cardiovascular care for decades. Continuous 24-hour blood pressure monitoring is widely understood to give physicians the most accurate picture of a patient's heart health — capturing critical morning surges and overnight patterns that single readings miss. Yet the traditional method, an inflatable cuff that tightens repeatedly around the upper arm through the day and night, has proven so uncomfortable that many patients refuse it and many physicians have stopped recommending it.
The ring changes the equation entirely. Slipped onto a finger, it records blood pressure automatically without compression, without disrupting sleep, without intruding on daily life. That shift in form factor has made patients willing to undergo monitoring they previously avoided — and the clinical data it unlocks allows doctors to diagnose more precisely and personalize treatment in ways that were previously impossible.
The technology's credibility received formal institutional backing when Korea's Society of Hypertension updated its 2026 clinical guidelines to explicitly permit validated cuffless monitors, removing any remaining hesitation among hospitals and physicians about adopting the device.
Sky Labs' leadership sees the Korean rollout not as an endpoint but as a proof of concept. The discomfort of traditional monitoring, the reluctance of patients, and the resulting gaps in cardiovascular data are universal problems — and the company is now setting its sights on international markets where the same friction awaits the same solution.
A South Korean medical device company announced this week that its fingertip blood pressure monitor has now been installed across the country's most prestigious hospital system. Sky Labs' CART BP pro, a ring worn on the finger, is now in use at 38 of Korea's 47 tertiary general hospitals—a penetration rate of 81 percent. The adoption includes all five of the nation's largest hospital networks, plus roughly 1,920 smaller clinics and medical centers nationwide.
The speed of this uptake is striking. The device launched just 18 months ago, yet it has already become standard equipment in the vast majority of Korea's top-tier medical institutions. The company attributes this rapid acceptance to a fundamental problem the ring solves: the discomfort of traditional blood pressure monitoring.
For decades, doctors have known that measuring a patient's blood pressure over a full 24-hour period—including sleep—provides the most accurate picture of their cardiovascular health. Yet most patients have resisted this kind of continuous monitoring because it requires an inflatable cuff wrapped around the upper arm that tightens repeatedly throughout the day and night, often causing skin irritation and disrupting sleep. Many physicians, aware of this burden, have simply stopped recommending the test, even when it would be clinically valuable.
The CART BP pro eliminates that friction entirely. A patient slips the ring onto a finger and goes about their day. The device automatically records blood pressure readings without any cuff, without any compression, without any interruption to normal life or sleep. This seemingly small change in form factor has opened a door that was previously closed: patients are now willing to undergo 24-hour monitoring because it no longer feels like a burden.
The clinical payoff is substantial. When doctors can see a patient's blood pressure patterns across a full day and night—including the critical morning hours when cardiovascular events often occur, and including the variability that reveals how well a patient's condition is controlled—they can make more precise diagnoses and tailor treatment more carefully to the individual. The data the ring captures is often impossible to obtain through conventional methods.
The device's adoption has been further legitimized by the medical establishment itself. In 2026, Korea's Society of Hypertension updated its clinical guidelines to explicitly permit the use of validated cuffless blood pressure monitors in medical practice. This institutional endorsement has given hospitals and physicians formal permission to prescribe the technology, removing any lingering hesitation about whether it was truly acceptable for clinical use.
Sky Labs' CEO Lee Byung-hwan framed the Korean market success as validation of the company's technology and a springboard for global expansion. The company now plans to pursue international markets, banking on the fact that the clinical problems the ring solves—patient discomfort, physician reluctance, the difficulty of capturing meaningful 24-hour data—are universal challenges in hypertension management, not unique to Korea. What has worked in Seoul and Busan may work in Tokyo, Singapore, and beyond.
Citações Notáveis
The growing adoption and prescription of CART BP pro at major tertiary hospitals in Korea serves as an objective indicator of the device's clinical effectiveness recognized by both healthcare professionals and the market.— Sky Labs CEO Lee Byung-hwan
A Conversa do Hearth Outra perspectiva sobre a história
Why did hospitals resist this kind of continuous monitoring before, if doctors knew it was medically valuable?
Because they were asking patients to wear something uncomfortable for a full day and night. A cuff that inflates repeatedly, that causes skin irritation, that wakes you up. Most people said no. Doctors stopped asking.
And the ring changes that equation entirely?
Completely. You put it on your finger and forget about it. No cuff, no compression, no disruption. Suddenly patients are willing to do something they refused to do before.
But is the data actually better, or just more abundant?
Both. You get more readings, yes, but you also capture patterns you couldn't see before—what happens at night, what happens in the morning, how much the pressure varies. That variability itself is clinically important. It tells you things about how well the condition is controlled.
The adoption rate is remarkable for an 18-month-old device. What explains that speed?
The clinical need was always there. Doctors wanted to do this test. Patients just wouldn't tolerate the old way. Once you remove the barrier, adoption happens fast.
Does the fact that Korea's major hospitals adopted it first matter for the company's global plans?
Enormously. It's not just a sales number. It's validation from the medical institutions that matter most. When the Big Five hospitals in Korea are using something, it signals to the world that this is real clinical technology, not a gadget.